Vizient examines pulsed field ablation, wearables for women’s cardiovascular health in latest Medical Device Tech Watch
June 20 2024 - 3:00PM
Business Wire
Vizient, Inc. examines pulsed field ablation technologies for
atrial fibrillation and the role wearable monitoring devices can
play in women’s cardiovascular health in the latest Medical Device
Tech Watch.
“New technologies—like pulsed field ablation and wearable heart
monitoring—and clinical decision support tools present providers
with the opportunity to improve care pathways and determine how to
provide cost-effective care,” said Bonnie Lai, senior vice
president and general manager, Vizient. “By working closely with
providers, we have developed best practices for operationalizing
the use of these innovative technologies and tools.”
Featured articles include:
Top three questions providers are asking about the latest in
electrophysiology technology: pulsed field ablation — As atrial
fibrillation becomes more common and poses a greater burden on
patients and healthcare systems, a need has arisen for efficient
and coordinated cardiovascular care. The promising clinical results
from pulsed field ablation (PFA) have generated a wave of
enthusiasm and interest with a major study reporting a 60-70%
success rate for patients living a-fib free after one year. Supply
utilization and reimbursement policies will determine the margin
impact of PFA. But with a lower risk of injury than other a-fib
ablation modalities, most hospitals with comprehensive
electrophysiology programs are exploring this new technology.
How women’s cardiovascular care differs and the role of
wearable technologies — Addressing gaps in care for women with
heart disease is crucial. Providers can narrow the gap between men
and women by identifying and understanding women’s unique risk
factors and heart disease symptoms, such as fatigue, jaw or tooth
pain and emphasizing disease prevention. As new generations of
wearable heart monitoring devices emerge, increasing accuracy and
functionality, uptake is generally higher among women compared to
men, but adoption rates lag overall among adults over 50 and
patients with lower incomes. Higher adoption rates could be
leveraged to improve care.
How can healthcare providers and their patients benefit from
clinical decision support tools? Clinical decision support
tools offer healthcare providers the ability to automate
operations, reduce the cost of care and enable collaboration among
clinicians. Not only does the new technology benefit patients and
insurance providers, but its use will also be a requirement by the
Centers for Medicare and Medicaid Services for imaging and lab
testing reimbursement under the Protecting Access to Medicare Act.
This article outlines the benefits of CDS, such as the help it
provides in assembling clinical evidence and aggregating drug
information as well as its obstacles.
Read more about Medical Device Tech Watch.
About Vizient, Inc.
Vizient, Inc., the nation’s largest provider-driven healthcare
performance improvement company, serves more than 65% of the
nation’s acute care providers, which includes 97% of the nation’s
academic medical centers, and more than 35% of the non-acute
market. Vizient provides expertise, analytics and consulting
services, as well as a contract portfolio that represents $140
billion in annual purchasing volume. Solutions and services from
Vizient improve the delivery of high-value care by aligning cost,
quality and market performance. Headquartered in Irving, Texas,
Vizient has offices throughout the United States. Learn more at
www.vizientinc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620162649/en/
Donna Ledbetter (972) 830-6321
donna.ledbetter@vizientinc.com